Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:BEAMNASDAQ:CNTANASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$6.05-0.2%$6.59$4.77▼$14.22$383.79M0.01155,101 shs186,573 shsBEAMBeam Therapeutics$16.99+1.9%$17.67$13.53▼$35.25$1.71B2.081.49 million shs1.84 million shsCNTACentessa Pharmaceuticals$12.68+0.6%$12.68$8.46▼$19.09$1.69B1.48713,894 shs1.38 million shsIMCRImmunocore$31.70-2.0%$31.58$23.15▼$41.54$1.59B0.83359,871 shs444,801 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%-13.82%+4.31%-18.02%-54.58%BEAMBeam Therapeutics0.00%-2.58%-4.28%-27.08%-26.67%CNTACentessa Pharmaceuticals0.00%+5.32%-3.94%-19.49%+48.91%IMCRImmunocore0.00%-11.03%-2.13%+6.34%-11.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax1.8866 of 5 stars3.52.00.00.00.00.80.6BEAMBeam Therapeutics3.2612 of 5 stars4.51.00.00.02.72.50.6CNTACentessa Pharmaceuticals3.3924 of 5 stars4.52.00.00.01.53.30.6IMCRImmunocore2.271 of 5 stars4.30.00.00.02.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.00Buy$31.00412.40% UpsideBEAMBeam Therapeutics 3.00Buy$48.75186.93% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.89119.94% UpsideIMCRImmunocore 2.55Moderate Buy$58.8985.77% UpsideCurrent Analyst Ratings BreakdownLatest ABVX, CNTA, BEAM, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.004/30/2025ABVXAbivaxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/ABEAMBeam Therapeutics$63.52M26.90N/AN/A$8.86 per share1.92CNTACentessa Pharmaceuticals$6.85M247.21N/AN/A$3.05 per share4.16IMCRImmunocore$310.20M5.13N/AN/A$7.20 per share4.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)IMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)Latest ABVX, CNTA, BEAM, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25BEAMBeam TherapeuticsN/A8.818.81CNTACentessa Pharmaceuticals0.2814.3714.37IMCRImmunocore1.036.366.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%BEAMBeam Therapeutics99.68%CNTACentessa Pharmaceuticals82.01%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ABEAMBeam Therapeutics3.50%CNTACentessa Pharmaceuticals7.09%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6163.44 millionN/ANot OptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableCNTACentessa Pharmaceuticals200133.55 million124.09 millionOptionableIMCRImmunocore32050.23 million45.01 millionOptionableABVX, CNTA, BEAM, and IMCR HeadlinesRecent News About These CompaniesImmunocore (NASDAQ:IMCR) Trading Down 3.4% - Here's WhyJune 16, 2025 | marketbeat.comImmunocore’s SWOT analysis: stock outlook amid pipeline progress, market challengesJune 15, 2025 | investing.comImmunocore (NASDAQ:IMCR) Upgraded by Wall Street Zen to "Buy" RatingJune 15, 2025 | americanbankingnews.comImmunocore (NASDAQ:IMCR) Rating Increased to Buy at Wall Street ZenJune 14, 2025 | marketbeat.comCantor Fitzgerald Comments on Immunocore FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates Immunocore FY2026 EarningsJune 10, 2025 | marketbeat.comGAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)June 10, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Shares Down 4.5% - What's Next?June 9, 2025 | marketbeat.comWall Street Zen Downgrades Immunocore (NASDAQ:IMCR) to HoldJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Grows Position in Immunocore Holdings plc (NASDAQ:IMCR)June 6, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Given "Buy" Rating at HC WainwrightJune 2, 2025 | marketbeat.comWall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a BetJune 2, 2025 | zacks.comImmunocore to present at the 2025 Jefferies Global Healthcare ConferenceJune 2, 2025 | globenewswire.comImmunocore (NASDAQ:IMCR) Trading Up 6.3% - Here's WhyMay 30, 2025 | marketbeat.comBank of America Corp DE Sells 95,362 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 29, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Shares Gap Up - What's Next?May 28, 2025 | marketbeat.comDeutsche Bank Aktiengesellschaft Begins Coverage on Immunocore (NASDAQ:IMCR)May 28, 2025 | marketbeat.comJefferies Financial Group Inc. Buys New Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 28, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 26, 2025 | marketbeat.comWoodline Partners LP Has $9.68 Million Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)May 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVX, CNTA, BEAM, and IMCR Company DescriptionsAbivax NASDAQ:ABVX$6.05 -0.01 (-0.17%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$6.04 0.00 (-0.08%) As of 06/18/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Beam Therapeutics NASDAQ:BEAM$16.99 +0.32 (+1.92%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$17.16 +0.17 (+0.99%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$12.68 +0.08 (+0.63%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$13.29 +0.61 (+4.81%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Immunocore NASDAQ:IMCR$31.70 -0.66 (-2.04%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$31.72 +0.02 (+0.06%) As of 06/18/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
